Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended June 30, 2024, for Inhibrx Biosciences, Inc. (INBX). The Company is a clinical-stage biopharmaceutical firm focused on oncology. The reporting period is defined by a major corporate restructuring: on May 30, 2024, the Company completed a separation from its former parent, Inhibrx, Inc. (the "Former Parent"), and a merger with Aventis Inc. (a Sanofi subsidiary, the "Acquirer"). The Former Parent spun off its INBRX-101 asset to the Acquirer, while Inhibrx Biosciences emerged as a standalone public company retaining its oncology pipeline (ozekibart/INBRX-109 and INBRX-106). Financial statements for periods prior to the spin-off are presented as if the separation had already occurred.
Key Financial Metrics
| Metric | Q2 2024 (3 Months) | YTD 2024 (6 Months) | Q2 2023 (3 Months) | YTD 2023 (6 Months) |
|---|---|---|---|---|
| Revenue | $0.1 million | $0.1 million | $0.03 million | $0.05 million |
| Net Income (Loss) | $1,858.0 million | $1,779.3 million | ($47.1) million | ($96.0) million |
| Operating Loss | ($160.9) million | ($234.7) million | ($41.3) million | ($85.1) million |
| Research & Development Expense | $67.6 million | $131.5 million | $34.1 million | $71.5 million |
| General & Administrative Expense | $93.4 million | $103.3 million | $7.3 million | $13.7 million |
| Cash and Cash Equivalents | $226.9 million | $226.9 million | $277.9 million (Dec 31, 2023) | $192.5 million (Jun 30, 2023) |
| Long-Term Debt | $0 | $0 | $207.0 million (Dec 31, 2023) | $207.0 million (Dec 31, 2023) |
| Net Cash Used in Operating Activities | N/A | ($120.4) million | N/A | ($82.2) million |
Note: Net income for 2024 is driven entirely by a non-recurring gain related to the corporate transaction.
Material Changes vs. Prior Period
- Transaction Gain: The Company recorded a $2.02 billion gain related to the transaction with the Acquirer. This includes $1.73 billion for merger consideration, $211.3 million for the extinguishment of debt assumed by the Acquirer, $14.5 million for net assets related to the spun-off INBRX-101 business, and $68.0 million in reimbursed transaction costs.
- Debt Extinguishment: The Acquirer assumed the Company's $200 million Amended 2020 Loan Agreement. Consequently, long-term debt dropped from $207 million at year-end 2023 to $0 at June 30, 2024.
- Expense Surge: Operating expenses increased significantly compared to the prior year.
- R&D: Increased 98% QoQ and 84% YTD, driven by $25.9 million in accelerated stock-based compensation and higher contract manufacturing costs.
- G&A: Increased 1,186% QoQ and 657% YTD, primarily due to $67.5 million in transaction-related costs (legal, advisory, SEC fees) and $15.2 million in accelerated stock-based compensation.
- Liquidity: Cash balances decreased by $51.1 million YTD due to operating cash burn, partially offset by $71.7 million in financing proceeds from stock option exercises.
Outlook, Risks, and Management Commentary
- Guidance: Management does not provide specific financial guidance. They state that existing cash ($226.9 million) is sufficient to fund operations for at least 12 months from the filing date.
- Pipeline Focus: The Company is now solely focused on its oncology pipeline:
- ozekibart (INBRX-109): Tetravalent DR5 agonist. Phase 2 data in chondrosarcoma expected mid-2025.
- INBRX-106: Hexavalent OX40 agonist. Seamless Phase 2/3 trial initiated in head and neck squamous cell carcinoma (HNSCC) in combination with Keytruda. Initial Phase 2 data expected H2 2025.
- Risks:
- Litigation: Ongoing trade secret misappropriation lawsuit filed by I-Mab Biopharma against the Former Parent and the Company's CSO. Trial scheduled for late October 2024; damages are not estimable.
- Capital Needs: The Company expects to continue incurring net losses until commercialization. Future funding may require equity or debt offerings, which could dilute shareholders.
- Development Uncertainty: Clinical trial timelines and costs are unpredictable; failure to achieve milestones could materially impact the business.
Investor Verification Checklist
- Transaction Accounting: Verify the classification of the $2.02 billion gain as a non-recurring item and confirm it does not reflect ongoing operational profitability.
- Run-Rate Expenses: Analyze operating expenses excluding the one-time transaction costs ($67.5M in G&A) and accelerated stock-based compensation ($41.1M total) to determine the true cash burn rate for future quarters.
- Cash Runway: Confirm the 12-month liquidity runway based on the current cash balance of $226.9 million and the adjusted operating burn rate.
- Debt Status: Confirm that the $200 million debt obligation has been fully extinguished and assumed by the Acquirer with no residual liability to Inhibrx Biosciences.
- Litigation Exposure: Monitor the I-Mab Biopharma lawsuit scheduled for trial in October 2024 for potential financial impact.